Answers are grounded in this paper and cite their sources.
Case report shows buprenorphine transdermal patch induces intractable vomiting in a patient, suggesting careful monitoring is needed.
Buprenorphine transdermal patches (TPs) are used for the management of both acute and chronic pain of varied aetiologies. They offer a convenient and sustained method of drug delivery with a good safety profile. Though nausea and/or vomiting have been reported with buprenorphine TP, intractable vomiting (without spontaneous resolution) has never been reported before. We report a 45-year-old female who presented with acute exacerbation of chronic low back pain with radiculopathy of bilateral lower limbs. We offered her conservative management initially. Buprenorphine TP (10 mcg/hour) was applied along with the prescription of a few oral medications. However, the subsequent day, she visited our clinic again with complaints of 6–7 episodes of vomiting with persistent nausea over the past 24 hours. Buprenorphine TP-induced vomiting was suspected. The patch was removed promptly, and rescue antiemetics were administered. Monitoring of patients on opioids, even with TPs, is warranted.
No takes yet. Share an insight, caveat, or question.
Khandelwal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: